BioVersys BV100 Data Show Strong Lung Penetration and Manageable Drug Interactions, Bolstering Phase 3 Case

BioVersys announced peer-reviewed publications showing its antibiotic BV100 achieves high lung concentrations and has a milder drug-interaction profile than rifampicin, strengthening the rationale for its Phase 3 trial in deadly CRAB pneumonia.

Chicago Metrowire Staff
••Healthcare
BioVersys BV100 Data Show Strong Lung Penetration and Manageable Drug Interactions, Bolstering Phase 3 Case

BioVersys AG has published two Phase 1 clinical pharmacology studies of its lead antibiotic candidate BV100 in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy, providing key data on lung penetration and drug-drug interactions that could shape the drug's future in treating severe hospital-acquired infections. The publications are important because they address critical pharmacological questions for an intravenous antibiotic intended for critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a pathogen with limited treatment options and mortality rates up to 50%.

The lung penetration study, published in the International Journal of Antimicrobial Agents, enrolled 36 healthy male participants who received intravenous rifabutin 300 mg every 12 hours for four days. Results showed that concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. According to the authors, these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia. The full study is available via 10.1016/j.ijantimicag.2026.108014.

The drug-interaction studies, published in the Journal of Antimicrobial Chemotherapy, characterized BV100's effects on CYP3A enzymes. Across two Phase 1 trials, BV100 was found to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold when co-administered with itraconazole. This profile is milder than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated. The milder interaction profile is significant because critically ill patients often receive multiple medications, making fewer drug interactions a clinical advantage. The study details are accessible through DOI: 10.1093/jac/dkag317.

These Phase 1 datasets form part of the clinical pharmacology foundation for RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by CRABC. Enrollment is ongoing, with topline data anticipated in early 2028. BV100 is also being studied in the open-label Phase 2b differentiation trial, RIV-CARE, in collaboration with ADVANCE-ID. In September 2026, BV100 received Fast Track Designation from the US FDA, building on its Qualified Infectious Disease Product designation granted in 2019.

The implications of these publications extend beyond BioVersys. With CRABC infections surpassing one million annually and resistance rates trending upward, a new intravenous option with favorable lung exposure and a manageable interaction profile could offer a much-needed alternative for clinicians. Dr. Glenn Dale, Chief Development Officer of BioVersys, noted that the papers address questions that matter most for an intravenous antibiotic in critically ill pneumonia patients. Dr. Marc Gitzinger, CEO and founder, added that the data strengthen the scientific basis for BV100 therapy in CRABC pneumonia. As the Phase 3 trial progresses, these published findings may support regulatory review and clinical adoption if BV100 ultimately reaches the market.

Blockchain Registration

QR Code for Blockchain Registration